BREAST CANCER

An expert on HER2+ breast cancer discusses exciting advancements in the treatment landscape, highlighting the DESTINY-Breast03 trial and trastuzumab deruxtecan.

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.

Rebecca A. Shatsky, MD, discusses the KATHERINE trial investigating adjuvant trastuzumab emtansine (T-DM1) in patients with residual invasive HER2+ breast cancer following neoadjuvant therapy.

Dr Shatsky discusses pertuzumab as a treatment for patients with HER2+ breast cancer, highlighting its mechanism of action as a HER2 dimerization inhibitor and updated data from the APHINITY trial.

The biologics license application from the FDA is supported by data from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in HR-positive, HER2-negative breast cancer.

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.

A medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.

In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.

Virginia Kaklamani, MD, DSc, explores strategies for mitigating fatigue, nausea, vomiting, and other toxicities and adverse events that may arise when patients receive endocrine therapy in combination with CDK4/6 inhibitors.

Virginia Kaklamani, MD, DSc, discusses the impact of the Phase III EMERALD trial results on the treatment landscape of HR+/HER2-low metastatic breast cancer, emphasizing the importance of selecting optimal drug combinations while minimizing toxicity profiles.

Virginia Kaklamani, MD, DSc, presents a case of metastatic breast cancer, initially responsive to first-line aromatase and CDK4/6 inhibitors, that progressed after 32 months. She explores using biomarker testing to identify ESR1 and other actionable mutations potentially causing endocrine resistance, guiding the transition to second-line therapy.

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.

In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

In the first article in a 2-part series, William J. Gradishar, MD, discusses the importance of elacestrant for treating patients with ESR1 positive metastatic breast cancer.

Samilia Obeng-Gyasi, MD, MPH, delved into the background and findings of this study assessing the correlation between neighborhood opportunity, allostatic load, and all-cause mortality among patients with breast cancer.

Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.

In an interview for Triple-Negative Breast Cancer Awareness Day, Daniel Carlson, DO, delved into the complexities of the disease, highlighting the current space and future possibilities.

Rebecca A. Shatsky, MD, discusses the outcomes of the phase 3 FeDeriCa study of subcutaneous trastuzumab and pertuzumab in patients with HER2-positive breast cancer.

Allina Health Cancer Institute and Astrin Biosciences are jointly integrating AI to improve the assessment of cancer cells in blood samples, beginning with breast cancer, which faces challenges with mammogram imaging and demands innovative solutions.

Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.

Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.

Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.

Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.

Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.

Following a favorable independent data monitoring committee review, the phase 3 PRESERVE 2 trial of trilaciclib in the first-line for patients with metastatic triple negative breast cancer treatment will move forward.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joyce O'Shaughnessy, MD, reviewed the current state of CDK4/6 inhibitor therapy for patients with advanced estrogen-receptor positive breast cancer.

A trial investigating REM-001 therapy in cutaneous metastatic breast cancer has been initiated.

In the second article of a 2-part series, Komal Jhaveri, MD, leads a discussion on the considerations physicians must have when looking to give elacestrant to patients with estrogen receptor–positive, HER2 negative metastatic breast cancer.

Chirag Shah, MD, discussed findings from the PREDICT study which looked at DCISionRT testing for patients with ductal carcinoma in situ breast cancer.

Goserelin is now included in the NCCN Breast Cancer Panel guidelines at 2 dosing schedules for ovarian function suppression in Version 1.2024.